Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
Immunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% of HCC exhibits intrinsic resistance to ICIs, making new therapeutic combinations urgently needed. The dysregulat...
Saved in:
| Main Authors: | Annapaola Montagner, Andrea Arleo, Fabrizia Suzzi, Antonino B. D’Assoro, Fabio Piscaglia, Laura Gramantieri, Catia Giovannini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01) -
Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01) -
Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma
by: Wang CH, et al.
Published: (2025-07-01) -
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01) -
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)